AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer.
The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy.
It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer.
The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Country | United States |
IPO Date | Nov 7, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 7 |
CEO | Dr. J. Mel Sorensen M.D. |
Contact Details
Address: 2 West Liberty Boulevard Malvern, Pennsylvania United States | |
Website | https://www.galeratx.com |
Stock Details
Ticker Symbol | GRTX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001563577 |
CUSIP Number | 36338D108 |
ISIN Number | US36338D1081 |
Employer ID | 46-1454898 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. J. Mel Sorensen M.D. | Chief Executive Officer, President & Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 14, 2025 | D | Filing |
Jan 13, 2025 | D | Filing |
Jan 02, 2025 | 4 | Filing |
Jan 02, 2025 | 3 | Filing |
Jan 02, 2025 | 4 | Filing |
Jan 02, 2025 | 3 | Filing |
Dec 31, 2024 | 8-K | Current Report |
Dec 20, 2024 | 8-K | Current Report |
Dec 13, 2024 | 10-Q | Quarterly Report |
Nov 15, 2024 | NT 10-Q | Filing |